NEWTON, Mass.--(BUSINESS WIRE)--Matritech (Amex: MZT), a leading developer and marketer of protein-based diagnostic products for the early detection of cancer, today reported financial results for the fourth quarter and fiscal year ended December 31, 2006. Revenues from sales of the NMP22® BladderChek® Test increased 37% in the fourth quarter 2006 and 31% for the year over those reported for the same periods in 2005. The Company achieved its 2006 revenue guidance of $12 million.
